$1.17 Billion is the total value of Camber Capital Management LP's 44 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDCO | MEDICINES CO | $94,900,000 | +32.7% | 2,500,000 | 0.0% | 8.13% | +66.9% | |
| CYBX | CYBERONICS INC | $60,780,000 | +2.2% | 1,000,000 | 0.0% | 5.21% | +28.6% | |
| NUVA | NUVASIVE INC | $53,042,000 | +1.8% | 1,100,000 | 0.0% | 4.54% | +28.0% | |
| OFIX | ORTHOFIX INTL N V | $50,625,000 | +1.9% | 1,500,000 | 0.0% | 4.34% | +28.2% | |
| LH | LABORATORY CORP AMER HLDGS | $43,388,000 | -10.5% | 400,000 | 0.0% | 3.72% | +12.6% | |
| CCRN | CROSS CTRY HEALTHCARE INC | $20,330,000 | +7.3% | 1,493,765 | 0.0% | 1.74% | +35.0% | |
| KND | KINDRED HEALTHCARE INC | $17,325,000 | -22.4% | 1,100,000 | 0.0% | 1.48% | -2.4% | |
| INNOCOLL AGsponsored adr | $14,089,000 | -13.8% | 1,111,111 | 0.0% | 1.21% | +8.4% | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $8,584,000 | -39.5% | 7,274,577 | 0.0% | 0.74% | -23.9% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS IN | $8,166,000 | -22.6% | 1,847,500 | 0.0% | 0.70% | -2.5% | |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $6,182,000 | -11.2% | 9,000,000 | 0.0% | 0.53% | +11.8% | ||
| BIOL | BIOLASE INC | $4,799,000 | -48.3% | 5,332,394 | 0.0% | 0.41% | -35.0% | |
| CRDC | CARDICA INC | $2,412,000 | -42.3% | 8,374,846 | 0.0% | 0.21% | -27.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.